UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)

OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS

UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 0-21643

Gilead Palo Alto, Inc. (formerly CV Therapeutics, Inc.)

 

 

(Exact name of registrant as specified in its charter)

 

3172 Porter Drive

Palo Alto, CA 94304

(650) 384-8500

 

 

(Address, including zip code, and telephone number,

including area code, of registrant’s principal executive offices)

 

Common Stock, par value $0.001 per share

 

 

(Title of each class of securities covered by this Form)

 

N/A

 

(Titles of all other classes of securities for which a duty to file

reports under Section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)    x
Rule 12g-4(a)(2)    ¨
Rule 12h-3(b)(1)(i)    x
Rule 12h-3(b)(1)(ii)    ¨
Rule 15d-6    ¨

Approximate number of holders of record as of the certification or notice date:         One        

Pursuant to the requirements of the Securities Exchange Act of 1934, Gilead Palo Alto, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: April 17, 2009     By:   / S / G REGG H. A LTON
      Gregg H. Alton
      Secretary
CV Therapeutics (NASDAQ:CVTX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 CV Therapeutics 차트를 더 보려면 여기를 클릭.
CV Therapeutics (NASDAQ:CVTX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 CV Therapeutics 차트를 더 보려면 여기를 클릭.